{"log_id": 8370784889540599723, "direction": 0, "words_result_num": 37, "words_result": [{"probability": {"variance": 0.000144, "average": 0.993677, "min": 0.95034}, "location": {"width": 1617, "top": 315, "height": 66, "left": 278}, "words": "1.目前尚无本品与其他化疗药物联合应用的数据,如与其他化疗药物联合应用,可能会"}, {"probability": {"variance": 0.006018, "average": 0.974867, "min": 0.618918}, "location": {"width": 1088, "top": 376, "height": 54, "left": 198}, "words": "增加不良反应发生率及严重程度,请在医师指导下谨慎使用"}, {"probability": {"variance": 0.009708, "average": 0.963777, "min": 0.539332}, "location": {"width": 1617, "top": 439, "height": 63, "left": 278}, "words": "2.在动物试验中曾发现本品可引起卵泡发障碍和精子生成缔碍,因此育龄期男性和有"}, {"probability": {"variance": 0.007744, "average": 0.958185, "min": 0.641079}, "location": {"width": 833, "top": 502, "height": 51, "left": 198}, "words": "龄妇女在用药期间及停药后8周内应注意避孕"}, {"probability": {"variance": 0.003597, "average": 0.982159, "min": 0.663627}, "location": {"width": 1620, "top": 574, "height": 57, "left": 278}, "words": "3对于出现胃肠道穿孔、需要临床处理的伤口裂开、瘘、肾病综合征的患者,发生期间应"}, {"probability": {"variance": 5.5e-05, "average": 0.992439, "min": 0.979946}, "location": {"width": 169, "top": 643, "height": 51, "left": 195}, "words": "停用本品"}, {"probability": {"variance": 2.1e-05, "average": 0.996612, "min": 0.984162}, "location": {"width": 485, "top": 709, "height": 48, "left": 209}, "words": "【孕妇及哺乳期妇女用药】"}, {"probability": {"variance": 0.013993, "average": 0.863294, "min": 0.745003}, "location": {"width": 89, "top": 772, "height": 45, "left": 278}, "words": "妊娠"}, {"probability": {"variance": 0.013253, "average": 0.953594, "min": 0.491462}, "location": {"width": 1620, "top": 833, "height": 63, "left": 275}, "words": "本品目前尚无用于妊娠期女性的相关资料。动物试验表明,在器宫发生期SD大鼠给予高"}, {"probability": {"variance": 0.001648, "average": 0.978188, "min": 0.780572}, "location": {"width": 1706, "top": 893, "height": 66, "left": 192}, "words": "剂量阿帕替尼6mg/kg日),可以使胎鼠骨骼发育延迟并有致畸效应。建议育龄女性在接受"}, {"probability": {"variance": 0.017241, "average": 0.952157, "min": 0.497959}, "location": {"width": 1703, "top": 947, "height": 80, "left": 195}, "words": "本品治疗期间和治疗结束至少8周内应采用必要的避孕措施。如在妊娠期间服用本品,应告知"}, {"probability": {"variance": 0.01029, "average": 0.974986, "min": 0.501596}, "location": {"width": 1002, "top": 1019, "height": 51, "left": 198}, "words": "患音可能对胎产生的危害,包括发育障碍和严重畸形"}, {"probability": {"variance": 0.030364, "average": 0.910985, "min": 0.562496}, "location": {"width": 218, "top": 1080, "height": 48, "left": 272}, "words": "哺乳期使用"}, {"probability": {"variance": 0.015, "average": 0.951384, "min": 0.454648}, "location": {"width": 1614, "top": 1146, "height": 60, "left": 281}, "words": "本品目前尚无用于哺乳期女性的相关资料。尚不清楚本品是否经人乳汁排泄,由于多种药"}, {"probability": {"variance": 0.014717, "average": 0.94878, "min": 0.5057}, "location": {"width": 1344, "top": 1203, "height": 63, "left": 192}, "words": "物都经人乳汁排泄,因此建议哺乳妇女在接受本品治疗期间停止母乳喂养"}, {"probability": {"variance": 0.000544, "average": 0.986537, "min": 0.934494}, "location": {"width": 232, "top": 1260, "height": 57, "left": 206}, "words": "【儿童用药】"}, {"probability": {"variance": 0.008038, "average": 0.969112, "min": 0.491393}, "location": {"width": 1611, "top": 1335, "height": 66, "left": 281}, "words": "目前尚无本品用于18岁以下患者的安全性和疗效资料,且无可参考文献,故不推荐18岁"}, {"probability": {"variance": 0.000196, "average": 0.988874, "min": 0.95861}, "location": {"width": 336, "top": 1398, "height": 48, "left": 195}, "words": "以下患者服用本品"}, {"probability": {"variance": 8e-06, "average": 0.996705, "min": 0.990671}, "location": {"width": 232, "top": 1467, "height": 45, "left": 203}, "words": "【老年用药】"}, {"probability": {"variance": 0.002512, "average": 0.976237, "min": 0.74453}, "location": {"width": 1614, "top": 1533, "height": 66, "left": 281}, "words": "目前尚无专门针对老年患者的临床研究资料。在本品Ⅱ、I期临床研究中,均纳入了大于"}, {"probability": {"variance": 0.003898, "average": 0.977676, "min": 0.648765}, "location": {"width": 1677, "top": 1605, "height": 57, "left": 198}, "words": "60岁小于70岁的老年晚期周癌患者,其中Ⅱ期研究中850mgqd组有12例,安慰剂组14例"}, {"probability": {"variance": 0.000539, "average": 0.987477, "min": 0.879583}, "location": {"width": 1706, "top": 1674, "height": 66, "left": 192}, "words": "Ⅲ期研究中试验组有7例,安慰剂组有39例,未观察到这些患者临床和实验室检查的特殊不"}, {"probability": {"variance": 0.001441, "average": 0.986922, "min": 0.767885}, "location": {"width": 1697, "top": 1743, "height": 68, "left": 195}, "words": "良反应,其药效与年龄小于60岁的患者无明显差异。对于70岁以上的患者,建议根据临床情"}, {"probability": {"variance": 9e-05, "average": 0.995523, "min": 0.96342}, "location": {"width": 1019, "top": 1815, "height": 54, "left": 192}, "words": "况和实验室检查指标在医师指导下慎用和调整用药剂量。"}, {"probability": {"variance": 0.000525, "average": 0.989661, "min": 0.929125}, "location": {"width": 318, "top": 1875, "height": 48, "left": 203}, "words": "【药物相互作用】"}, {"probability": {"variance": 7.4e-05, "average": 0.995791, "min": 0.965399}, "location": {"width": 706, "top": 1941, "height": 48, "left": 278}, "words": "本品尚未进行正式的药物相互作用研究"}, {"probability": {"variance": 0.007228, "average": 0.955412, "min": 0.667668}, "location": {"width": 789, "top": 2002, "height": 51, "left": 290}, "words": "CYP3A4抑制剂和诱导剂对阿帕替尼的影响"}, {"probability": {"variance": 0.010051, "average": 0.948662, "min": 0.545446}, "location": {"width": 1617, "top": 2065, "height": 54, "left": 272}, "words": "体外代谢酶研究表明,阿帕替尼主要由CYP3A4代谢:其次经CYP2D6、CYP2C9和CYP2E1"}, {"probability": {"variance": 0.006735, "average": 0.970125, "min": 0.533841}, "location": {"width": 1694, "top": 2125, "height": 54, "left": 195}, "words": "代谢。阿帕替尼与CYP3A4的强抑制剂(伊曲康唑、克拉霉素、伏立康噔、泰利霉素,沙"}, {"probability": {"variance": 0.005383, "average": 0.968322, "min": 0.702287}, "location": {"width": 1691, "top": 2185, "height": 51, "left": 195}, "words": "那韦、利托那韦等)同时应用时,可能会增加阿帕替尼的血浆浓度:与CYP3A4的诱导剂(地"}, {"probability": {"variance": 0.004812, "average": 0.970314, "min": 0.652076}, "location": {"width": 1694, "top": 2246, "height": 51, "left": 195}, "words": "塞米松、苯妥英,卡马西平、利福平、苯巴比妥、利潘喷汀等)同时应用时,可能减低阿帕替"}, {"probability": {"variance": 0.000882, "average": 0.987838, "min": 0.848651}, "location": {"width": 1694, "top": 2306, "height": 54, "left": 192}, "words": "尼的血浆浓度。当需与其他药物联用时,建议选择可替代的对CYP3A4酶无抑制或无诱导的"}, {"probability": {"variance": 0.010764, "average": 0.95957, "min": 0.399219}, "location": {"width": 1697, "top": 2369, "height": 54, "left": 192}, "words": "药物,如果须与CYP3A4酶强抑制剂或诱导剂同时应用,需要结合临床观察考是否进行"}, {"probability": {"variance": 0, "average": 0.999506, "min": 0.998811}, "location": {"width": 169, "top": 2432, "height": 43, "left": 192}, "words": "剂量调整"}, {"probability": {"variance": 0.002257, "average": 0.975213, "min": 0.83513}, "location": {"width": 514, "top": 2484, "height": 54, "left": 275}, "words": "阿帕替尼对其他药物的影响"}, {"probability": {"variance": 0.006065, "average": 0.968099, "min": 0.597223}, "location": {"width": 1611, "top": 2553, "height": 51, "left": 278}, "words": "体外研究表明,阿帕替尼对CYP3A4和CYP2C9有较强的抑制作用(IC30≤1M),因此"}, {"probability": {"variance": 0.000668, "average": 0.992105, "min": 0.833622}, "location": {"width": 1700, "top": 2613, "height": 57, "left": 192}, "words": "治疗期间应慎与主要经CYP3A4代谢的药物同时应用,如钙离子拮抗剂尼索地平和乐卡地平"}], "language": -1}